MME and diabetic kidney disease: Recent advancements in the field of diabetic complications have shed light on the potential therapeutic roles of neprilysin inhibitors, both as monotherapy and in combination with other agents, in the management of diabetic nephropathy (DKD) and diabetic cardiomyopathy (DCM).